37 completed. 37 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 37 | Completed 37 |
| Phase 1 | 2 | Completed 2 |
Follow Neurofibromatoses: new trials by email Literature Review of Neurofibromatoses trials Research Report on Neurofibromatoses
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) NFX-179 gel, Vehicle gel - Cutaneous Neurofibroma, Neurofibromatosis 1 | Phase 2 | Completed | NFlection Therapeutics, Inc. | 199 | 2021-09-29 | 2026-02-17 |
| Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1 N-Acetyl cysteine, Placebo - Neurofibromatosis 1 | Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 25 | 2021-02-23 | 2026-06-05 |
| NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) NFX-179 Gel, Vehicle Gel - Neurofibromatosis 1, Cutaneous Neurofibroma | Phase 2 | Completed | NFlection Therapeutics, Inc. | 48 | 2020-08-21 | 2022-08-09 |
| Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Crizotinib - Neurofibromatosis 2, Progressive Vestibular Schwannoma (VS) | Phase 2 | Completed | University of Alabama at Birmingham | 12 | 2020-02-18 | 2026-03-13 |
| SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors Selumetinib, Sirolimus - Malignant Peripheral Nerve Sheath Tumors, Neurofibromatosis 1 | Phase 2 | Completed | Sarcoma Alliance for Research through Collaboration | 21 | 2019-10-02 | 2026-05-27 |
| Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours Selumetinib - Neurofibromatosis Type 1, Plexiform Neurofibroma | Phase 1 / Phase 2 | Completed | Great Ormond Street Hospital for Children NHS Foundation Trust | 14 | 2019-09-26 | 2024-04-04 |
| Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1 N-acetylcysteine (NAC), Placebo - Neurofibromatosis 1 | Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 5 | 2019-01-15 | 2026-04-21 |
| Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas Binimetinib - Neurofibromatosis Type 1, Plexiform Neurofibroma | Phase 2 | Completed | University of Alabama at Birmingham | 45 | 2017-11-28 | 2025-05-02 |
| Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma Laboratory Biomarker Analysis, Selumetinib Sulfate - Cutaneous Neurofibroma, Neurofibromatosis Type 1 | Phase 2 | Completed | National Cancer Institute (NCI) | 11 | 2017-08-26 | 2023-12-06 |
| Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1 Diclofenac Sodium, Saline Solution - Neurofibromatosis 1, Cutaneous Neurofibroma | Phase 2 | Completed | Fundação Educacional Serra dos Órgãos | 7 | 2017-02-15 | 2017-10-26 |
| AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas AZD2014 - Neurofibromatosis 2, Meningioma | Phase 2 | Completed | Massachusetts General Hospital | 18 | 2016-08-31 | 2022-06-13 |
| Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Icotinib - Vestibular Schwannoma, Neurofibromatosis Type 2 | Phase 2 | Completed | Li Peng | 10 | 2016-07-01 | 2021-09-09 |
| Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T Everolimus - Neurofibromatosis 1 | Phase 2 | Completed | The University of Texas Health Science Center, Houston | 24 | 2015-02-01 | 2023-12-20 |
| MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1 PD-0325901 - Neurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PN | Phase 2 | Completed | University of Alabama at Birmingham | 19 | 2014-06-01 | 2019-01-10 |
| Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults Cabozantinib - NF1, Neurofibromatosis | Phase 2 | Completed | University of Alabama at Birmingham | 45 | 2014-06-01 | 2023-05-24 |
| Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Axitinib - Neurofibromatosis Type 2, Vestibular Schwannomas | Phase 2 | Completed | NYU Langone Health | 13 | 2014-04-01 | 2021-12-01 |
| Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Endostatin - Vestibular Schwannoma, Neurofibromatosis Type 2 | Phase 2 | Completed | Beijing Tiantan Hospital | 20 | 2014-01-01 | 2017-02-09 |
| Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas Bevacizumab - Neurofibromatosis Type 2, Progressive Vestibular Schwannomas | Phase 2 | Completed | University of Alabama at Birmingham | 22 | 2013-05-15 | 2021-02-12 |
| Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma Lenalidomide, Pharmacological Study - Neurofibromatosis Type 1, Recurrent Childhood Pilocytic Astrocytoma | Phase 2 | Completed | National Cancer Institute (NCI) | 75 | 2012-07-05 | 2025-01-07 |
| Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas Gleevec - Neurofibromatosis, Neurofibromas | Phase 1 / Phase 2 | Completed | Kent Robertson | 21 | 2012-02-01 | 2017-07-02 |
Showing 20 of 37. Sign in to see all of them.
Neurofibromatosis 1 (22) · Neurofibromatosis 2 (13) · Neurofibroma, Plexiform (8) · Neuroma, Acoustic (8) · Neurofibroma (6) · Meningioma (4) · Optic Nerve Glioma (3) · Brain Neoplasms (2) · Ependymoma (2) · Neurofibrosarcoma (2) · Astrocytoma (1) · Attention Deficit Disorder with Hyperactivity (1) · Central Nervous System Neoplasms (1) · Genetic Diseases, Inborn (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (37) · Heredodegenerative Disorders, Nervous System (37) · Neoplasms (37) · Neoplasms by Histologic Type (37) · Neoplasms, Nerve Tissue (37) · Neoplastic Syndromes, Hereditary (37) · Nervous System Diseases (37) · Neurocutaneous Syndromes (37) · Neurodegenerative Diseases (37) · Genetic Diseases, Inborn (36) · Nerve Sheath Neoplasms (36) · Neurofibroma (31) · Nervous System Neoplasms (27) · Neuromuscular Diseases (26)
Bevacizumab (3) · Everolimus (3) · Sirolimus (3) · AZD 6244 (2) · Acetylcysteine (2) · Imatinib Mesylate (2) · Inhalation (2) · pirfenidone (2) · Axitinib (1) · Celecoxib (1) · Crizotinib (1) · Diclofenac (1) · Doxorubicin (1) · Endostatins (1) · Etoposide (1)
University of Alabama at Birmingham (7) · National Cancer Institute (NCI) (5) · NYU Langone Health (3) · Assistance Publique - Hôpitaux de Paris (2) · Children's Hospital Medical Center, Cincinnati (2) · NFlection Therapeutics, Inc. (2) · Sarcoma Alliance for Research through Collaboration (2) · Beijing Tiantan Hospital (1) · Children's Hospital of Philadelphia (1) · Corewell Health West (1) · FDA Office of Orphan Products Development (1) · Fundação Educacional Serra dos Órgãos (1) · Great Ormond Street Hospital for Children NHS Foundation Trust (1) · Indiana University (1) · Kent Robertson (1)
United States (29) · Australia (2) · China (2) · France (2) · Brazil (1) · Canada (1) · Germany (1) · New Zealand (1) · United Kingdom (1)
Matthias A Karajannis, MD, MS (3) · Fu Zhao (2) · Pinan Liu (2) · AeRang Kim, MD, PhD (1) · Albert S Cornelius, MD (1) · Brian Weiss, MD (1) · Brigitte C Widemann, M.D. (1) · Brigitte C. Widemann, MD (1) · Brigitte Widemann, M.D. (1) · Brigitte Widemann, MD (1) · Bruce Korf, MD (1) · Bruce Korf, MD, PhD (1) · Bruce R Korf (1) · Chie-Schin Shih, MD (1) · Darren Hargrave, MB Bch (1)
PMID 23099009, PMID 24500418, PMID 24753394, PMID 26976425, PMID 27956565, PMID 30284154, PMID 30339775, PMID 32562630, PMID 33442015, PMID 33507822, PMID 33817379, PMID 36996759, PMID 37126770, PMID 38907342, PMID 40009403
P30CA006973 (1), P30CA013148 (1), U10CA098543 (1), U10CA180886 (1)